Afmedica Inc.
This article was originally published in Start Up
Executive Summary
It's not much of a stretch for companies to apply to other surgical markets the concepts that made drug-eluting stents such an overnight success. The overhealing response that characterizes in-stent restenosis is at the heart of many other processes that limit the long-term success of surgical interventions. In fact, Afmedica Inc. is building a drug plus device platform for vascular surgery around sirolimus, the very same drug that enabled Johnson & Johnson to be the first company to demonstrate that its drug-eluting stent prevents restenosis. Afmedica has built an IP estate around the use of the drug on the outside of vessels, where, in combination with non-inflammatory polymers, it might help reduce the failure of vascular access grafts for dialysis, prevent the closure of peripheral bypass grafts, and prevent surgical adhesions in abdominal surgery.
You may also be interested in...
The Fischell Family's Secret of Success
Meet the Fischells. Four members of one family are collectively responsible for filing more than 200 patents in the medical device field, founding more than 14 device companies, including NeuroPace, Neuralieve, Angel Medical, Svelte Medical and GlucoTec, and inventing the world's most widely-used implantable medical device in the history of the industry, the stent design sold by Johnson & Johnson as the Bx Velocity. START-UP interviews the four Fischells to learn the secrets of their success.
Breaking the Surgical Adhesion Barrier
Post-surgical adhesions occur almost any time a surgeon opens up a body cavity; in intra-abdominal surgery, for example, they form 85-90% of the time. But after a decade of trying, the medical device industry has only two adhesion prevention products to show for its efforts, and both products have drawbacks that have limited their market penetration. A new generation of companies--Confluent Surgical, Angiotech Pharmaceuticals, FzioMed, Sentrx Surgical, Afmedica, Kytogenics Pharmaceuticals, and ARC Pharmaceuticals, hope to profit from years of learning in the field to get new and improved products into the hands of surgeons .
Breaking the Surgical Adhesion Barrier
Post-surgical adhesions occur almost any time a surgeon opens up a body cavity; in intra-abdominal surgery, for example, they form 85-90% of the time. But after a decade of trying, the medical device industry has only two adhesion prevention products to show for its efforts, and both products have drawbacks that have limited their market penetration. A new generation of companies--Confluent Surgical, Angiotech Pharmaceuticals, FzioMed, Sentrx Surgical, Afmedica, Kytogenics Pharmaceuticals, and ARC Pharmaceuticals, hope to profit from years of learning in the field to get new and improved products into the hands of surgeons .